Effect of randomized treatment withdrawal of budesonide oral suspension on clinically relevant efficacy outcomes in patients with eosinophilic esophagitis: a post hoc analysis

Effect of randomized treatment withdrawal of budesonide oral suspension on clinically relevant efficacy outcomes in patients with eosinophilic esophagitis: a post hoc analysis

Background: Relapse after corticosteroid withdrawal in eosinophilic esophagitis is not well understood. Objectives: Budesonide oral suspension (BOS) 2.0 mg twice daily (b.i.d.) was evaluated in two consecutive phase III studies (12 and 36 weeks, respectively). For clinicopathologic responders after...

Full description

Saved in:
Bibliographic Details
Main Authors: Evan S. Dellon, Margaret H. Collins, David A. Katzka, Vincent A. Mukkada, Gary W. Falk, Wenwen Zhang, Bridgett Goodwin, Brian Terreri, Mena Boules, Nirav K. Desai, Ikuo Hirano
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848241307602
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items